(Reuters) - Valeant Pharmaceuticals International Inc said it increased its offer for Salix Pharmaceuticals Inc to $173 per share, hoping to end a bidding war with Endo International Plc for the bowel drug maker.
Valeant agreed to buy Salix last month for $158 per share in cash. Endo then offered about $175 per share in cash and stock for Salix last week.
Valeant's new offer provides Salix stockholders with an about $1 billion more in cash, Valeant said on Monday.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Savio D'Souza)
Relacionados
- Farmacéutica Endo ofrece 11.000 mln dlr por Salix, superando propuesta de Valeant
- Endo entra en batalla por Salix Pharmaceuticals y eleva la oferta de Valeant
- La farmacéutica Valeant paga 12.800 millones por Salix
- Canadiense Valeant comprará farmacéutica Salix por 10.100 mln dlrs
- Valeant adquiere la farmacéutica Salix por 12.822 millones
